Translational Stroke Research

, 2:266

Intracranial Delivery of Stem Cells

  • Keith W. Muir
  • John Sinden
  • Erik Miljan
  • Laurence Dunn
Cell-based Therapies for Stroke

Abstract

The method of delivery of stem cells is a major factor to consider in the design of clinical trials of cell therapy. Different methods of delivery will be associated with different risks to the patient, and may also be associated with different potential for benefit. Current approaches are partly informed by the routes selected for study in animal models of focal ischaemia and CNS transplantation, but there has been little work comparing the efficacy of different routes of administration. Direct intraparenchymal delivery of cells has been employed in several preliminary clinical trials, and data on the safety of this approach are reviewed.

Keywords

Stem cell Stroke Intracranial injection Clinical trial Safety 

References

  1. 1.
    Savitz SI, Chopp M, Deans R, Carmichael ST, Phinney D, Wechsler L. Stem cell therapy as an emerging paradigm for stroke (STEPS) II. Stroke. 2011;42:825–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Kondziolka D, Steinberg GK, Wechsler L, Meltzer CC, Elder E, Gebel J, et al. Neurotransplantation for patients with subcortical motor stroke: a phase 2 randomized trial. J Neurosurg. 2005;103:38–45.PubMedCrossRefGoogle Scholar
  3. 3.
    Kondziolka D, Wechsler L, Goldstein S, Meltzer C, Thulborn KR, Gebel J, et al. Transplantation of cultured human neuronal cells for patients with stroke. Neurology. 2000;55:565–9.PubMedGoogle Scholar
  4. 4.
    Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol. 2005;57:874–82.PubMedCrossRefGoogle Scholar
  5. 5.
    Bacigaluppi M, Pluchino S, Martino G, Kilic E, Hermann DM. Neural stem/precursor cells for the treatment of ischemic stroke. J Neurol Sci. 2008;265:73–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Shen LH, Li Y, Chen J, Zacharek A, Gao Q, Kapke A, et al. Therapeutic benefit of bone marrow stromal cells administered 1 month after stroke. J Cereb Blood Flow Metab. 2007;27:6–13.PubMedCrossRefGoogle Scholar
  7. 7.
    Seyfried D, Ding J, Han Y, Li Y, Chen J, Chopp M. Effects of intravenous administration of human bone marrow stromal cells after intracerebral hemorrhage in rats. J Neurosurg. 2006;104:313–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Chen J, Zhang ZG, Li Y, Wang L, Xu YX, Gautam SC, et al. Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ Res. 2003;92:692–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke. 2001;32:1005–11.PubMedCrossRefGoogle Scholar
  10. 10.
    Li Y, Chen J, Wang L, Lu M, Chopp M. Treatment of stroke in rat with intracarotid administration of marrow stromal cells. Neurology. 2001;56:1666–72.PubMedGoogle Scholar
  11. 11.
    Bliss TM, Kelly S, Shah AK, Foo WC, Kohli P, Stokes C, et al. Transplantation of hNT neurons into the ischemic cortex: cell survival and effect on sensorimotor behavior. J Neurosci Res. 2006;83:1004–14.PubMedCrossRefGoogle Scholar
  12. 12.
    Borlongan CV, Tajima Y, Trojanowski JQ, Lee VM, Sanberg PR. Transplantation of cryopreserved human embryonal carcinoma-derived neurons (NT2N cells) promotes functional recovery in ischemic rats. Exp Neurol. 1998;149:310–21.PubMedCrossRefGoogle Scholar
  13. 13.
    Rehncrona S. A critical review of the current status and possible developments in brain transplantation. Adv Tech Stand Neurosurg. 1997;23:3–46.PubMedCrossRefGoogle Scholar
  14. 14.
    Hallett M, Litvan I. Evaluation of surgery for Parkinson's disease: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. The Task Force on Surgery for Parkinson's Disease. Neurology. 1999;53:1910–21.PubMedGoogle Scholar
  15. 15.
    Lopez-Lozano JJ, Bravo G, Brera B, Dargallo J, Salmean J, Uria J, et al. Long-term follow-up in 10 Parkinson's disease patients subjected to fetal brain grafting into a cavity in the caudate nucleus: the Clinica Puerta de Hierro experience. CPH Neural Transplantation Group. Transplant Proc. 1995;27:1395–400.PubMedGoogle Scholar
  16. 16.
    Schumacher JM, Ellias SA, Palmer EP, Kott HS, Dinsmore J, Dempsey PK, et al. Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology. 2000;54:1042–50.PubMedGoogle Scholar
  17. 17.
    Fink JS, Schumacher JM, Ellias SL, Palmer EP, Saint-Hilaire M, Shannon K, et al. Porcine xenografts in Parkinson's disease and Huntington's disease patients: preliminary results. Cell Transplant. 2000;9:273–8.PubMedGoogle Scholar
  18. 18.
    Savitz SI, Dinsmore J, Wu J, Henderson GV, Stieg P, Caplan LR. Neurotransplantation of fetal porcine cells in patients with basal ganglia infarcts: a preliminary safety and feasibility study. Cerebrovasc Dis. 2005;20:101–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med. 2001;344:710–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003;54:403–14.PubMedCrossRefGoogle Scholar
  21. 21.
    Favre J, Taha JM, Burchiel KJ. An analysis of the respective risks of hematoma formation in 361 consecutive morphological and functional stereotactic procedures. Neurosurgery. 2002;50:48–56.PubMedGoogle Scholar
  22. 22.
    Sansur CA, Frysinger RC, Pouratian N, Fu KM, Bittl M, Oskouian RJ, et al. Incidence of symptomatic hemorrhage after stereotactic electrode placement. J Neurosurg. 2007;107:998–1003.PubMedCrossRefGoogle Scholar
  23. 23.
    Beric A, Kelly PJ, Rezai A, Sterio D, Mogilner A, Zonenshayn M, et al. Complications of deep brain stimulation surgery. Stereotact Funct Neurosurg. 2001;77:73–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Lyons KE, Wilkinson SB, Overman J, Pahwa R. Surgical and hardware complications of subthalamic stimulation: a series of 160 procedures. Neurology. 2004;63:612–6.PubMedGoogle Scholar
  25. 25.
    Binder DK, Rau GM, Starr PA. Risk factors for hemorrhage during microelectrode-guided deep brain stimulator implantation for movement disorders. Neurosurgery. 2005;56:722–32.PubMedCrossRefGoogle Scholar
  26. 26.
    Gorgulho A, De Salles AA, Frighetto L, Behnke E. Incidence of hemorrhage associated with electrophysiological studies performed using macroelectrodes and microelectrodes in functional neurosurgery. J Neurosurg. 2005;102:888–96.PubMedCrossRefGoogle Scholar
  27. 27.
    Polgar S, Morris ME, Reilly S, Bilney B, Sanberg PR. Reconstructive neurosurgery for Parkinson's disease: a systematic review and preliminary meta-analysis. Brain Res Bull. 2003;60:1–24.PubMedCrossRefGoogle Scholar
  28. 28.
    Lane EL, Björklund A, Dunnett SB, Winkler C. Neural grafting in Parkinson's disease unraveling the mechanisms underlying graft-induced dyskinesia. Prog Brain Res. 2010;184:295–309.PubMedCrossRefGoogle Scholar
  29. 29.
    Freeman TB, Cicchetti F, Bachoud-Lévi AC, Dunnett SB. Technical factors that influence neural transplant safety in Huntington's disease. Exp Neurol. 2011;227:1–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Rosser AE, Barker RA, Harrower T, Watts C, Farrington M, Ho AK, et al. Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475. J Neurol Neurosurg Psychiatr. 2002;73:678–85.PubMedCrossRefGoogle Scholar
  31. 31.
    Kondziolka D, Steinberg GK, Cullen SB, McGrogan M. Evaluation of surgical techniques for neuronal cell transplantation used in patients with stroke. Cell Transplant. 2004;13:749–54.PubMedCrossRefGoogle Scholar
  32. 32.
    Wenning GK, Odin P, Morrish P, Rehncrona S, Widner H, Brundin P, et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol. 1997;42:95–107.PubMedCrossRefGoogle Scholar
  33. 33.
    Hagell P, Schrag A, Piccini P, Jahanshahi M, Brown R, Rehncrona S, et al. Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. Brain. 1999;122(Pt 6):1121–32.PubMedCrossRefGoogle Scholar
  34. 34.
    Brundin P, Pogarell O, Hagell P, Piccini P, Widner H, Schrag A, et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain. 2000;123(Pt 7):1380–90.PubMedCrossRefGoogle Scholar
  35. 35.
    Peschanski M, Defer G, N'Guyen JP, Ricolfi F, Monfort JC, Remy P, et al. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain. 1994;117(Pt 3):487–99.PubMedCrossRefGoogle Scholar
  36. 36.
    Mendez I, Dagher A, Hong M, Hebb A, Gaudet P, Law A, et al. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line--derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. J Neurosurg. 2000;92:863–9.Google Scholar
  37. 37.
    Defer GL, Geny C, Ricolfi F, Fenelon G, Monfort JC, Remy P, et al. Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach. Brain. 1996;119(Pt 1):41–50.PubMedCrossRefGoogle Scholar
  38. 38.
    Jacques DB, Kopyov OV, Eagle KS, Carter T, Lieberman A. Outcomes and complications of fetal tissue transplantation in Parkinson's disease. Stereotact Funct Neurosurg. 1999;72:219–24.PubMedCrossRefGoogle Scholar
  39. 39.
    Henderson BT, Clough CG, Hughes RC, Hitchcock ER, Kenny BG. Implantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson's disease. Arch Neurol. 1991;48:822–7.PubMedGoogle Scholar
  40. 40.
    Sramka M, Rattaj M, Molina H, Vojtassak J, Belan V, Ruzicky E. Stereotactic technique and pathophysiological mechanisms of neurotransplantation in Huntington's chorea. Stereotact Funct Neurosurg. 1992;58:79–83.PubMedCrossRefGoogle Scholar
  41. 41.
    Madrazo I, Franco-Bourland RE, Castrejon H, Cuevas C, Ostrosky-Solis F. Fetal striatal homotransplantation for Huntington's disease: first two case reports. Neurol Res. 1995;17:312–5.PubMedGoogle Scholar
  42. 42.
    Kopyov OV, Jacques S, Lieberman A, Duma CM, Eagle KS. Safety of intrastriatal neurotransplantation for Huntington's disease patients. Exp Neurol. 1998;149:97–108.PubMedCrossRefGoogle Scholar
  43. 43.
    Hauser RA, Furtado S, Cimino CR, Delgado H, Eichler S, Schwartz S, et al. Bilateral human fetal striatal transplantation in Huntington's disease. Neurology. 2002;58:687–95.PubMedGoogle Scholar
  44. 44.
    Mendez I, Sanchez-Pernaute R, Cooper O, Vinuela A, Ferrari D, Bjorklund L, et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain. 2005;128:1498–510.PubMedCrossRefGoogle Scholar
  45. 45.
    Bachoud-Levi A, Bourdet C, Brugieres P, Nguyen JP, Grandmougin T, Haddad B, et al. Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease. Exp Neurol. 2000;161:194–202.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Keith W. Muir
    • 1
    • 3
  • John Sinden
    • 2
  • Erik Miljan
    • 2
  • Laurence Dunn
    • 3
  1. 1.Institute of Neuroscience and PsychologyUniversity of GlasgowGlasgowUK
  2. 2.ReNeuronGuildfordUK
  3. 3.Institute of Neurological Sciences, Southern General HospitalGlasgowUK

Personalised recommendations